Intellia Therapeutics, Inc., was incorporated in Delaware in May 2014. The company is a leading gene editing company focused on the development of unique, potentially curative therapies using a recently developed systematic biological tool known as CRISPR/Cas 9. The company believes that the CRISPR/Cas9 technology has the potential to modify drugs in the human body by permanently editing disease-associated genes with a single course of treatment. The company intends to use its leading scientific expertise, clinical development experience and intellectual property position to unlock the broad therapeutic applications of CRISPR/Cas9 gene editing and develop a new generation of therapeutic products with potential.